Another study on Epo’s neuroprotective role in term newborns with hypoxic-ischemic encephalopathy (HIE), the HEAL trial [46] reported no benefit of Epo (relative risk [RR] 1.03, p = 0.74) and an increase in adverse events. The gene discussed is EPO; the disease is perinatal asphyxia.